<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hathaway A</submitter><funding>British Heart Foundation</funding><funding>Pfizer UK</funding><pagination>826-838</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616671</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>204(3)</volume><pubmed_abstract>Despite significant global morbidity associated with respiratory infection, there is a paucity of data examining the association between severity of non-SARS-CoV-2 respiratory infection and blood group. We analysed a prospective cohort of adults hospitalised in Bristol, UK, from 1 August 2020 to 31 July 2022, including patients with acute respiratory infection (pneumonia [n = 1934] and non-pneumonic lower respiratory tract infection [NP-LRTI] [n = 1184]), a negative SARS-CoV-2 test and known blood group status. The likelihood of cardiovascular complication, survival and hospital admission length was assessed using regression models with group O and RhD-negative status as reference groups. Group A and RhD-positive were over-represented in both pneumonia and NP-LRTI compared to a first-time </pubmed_abstract><journal>British journal of haematology</journal><pubmed_title>Association of ABO and Rhesus blood groups with severe outcomes from non-SARS-CoV-2 respiratory infection: A prospective observational cohort study in Bristol, UK 2020-2022.</pubmed_title><pmcid>PMC7616671</pmcid><funding_grant_id>FS/4yPhD/F/21/34162</funding_grant_id><funding_grant_id>WI255886</funding_grant_id><funding_grant_id>FS/4yPhD/F/21/34162B</funding_grant_id><pubmed_authors>Taylor Z</pubmed_authors><pubmed_authors>Wright L</pubmed_authors><pubmed_authors>Jeenes-Flanagan M</pubmed_authors><pubmed_authors>Avon CAP Research Group</pubmed_authors><pubmed_authors>Gonzalez MG</pubmed_authors><pubmed_authors>Walters R</pubmed_authors><pubmed_authors>Osborne B</pubmed_authors><pubmed_authors>Adegbite D</pubmed_authors><pubmed_authors>Ruffino G</pubmed_authors><pubmed_authors>Fox K</pubmed_authors><pubmed_authors>Grimes C</pubmed_authors><pubmed_authors>Perkins F</pubmed_authors><pubmed_authors>Lazarus R</pubmed_authors><pubmed_authors>Bellavia M</pubmed_authors><pubmed_authors>Manning N</pubmed_authors><pubmed_authors>Challen R</pubmed_authors><pubmed_authors>Taylor A</pubmed_authors><pubmed_authors>Cloake J</pubmed_authors><pubmed_authors>Antico R</pubmed_authors><pubmed_authors>Smart L</pubmed_authors><pubmed_authors>Suppiah S</pubmed_authors><pubmed_authors>Finn A</pubmed_authors><pubmed_authors>Maskell N</pubmed_authors><pubmed_authors>Bridgeman E</pubmed_authors><pubmed_authors>Marlow R</pubmed_authors><pubmed_authors>Heath R</pubmed_authors><pubmed_authors>Grace N</pubmed_authors><pubmed_authors>Maughan K</pubmed_authors><pubmed_authors>Morrison L</pubmed_authors><pubmed_authors>McGuinness S</pubmed_authors><pubmed_authors>Wright JK</pubmed_authors><pubmed_authors>Tilzey G</pubmed_authors><pubmed_authors>Scott E</pubmed_authors><pubmed_authors>Croxford P</pubmed_authors><pubmed_authors>Griffiths O</pubmed_authors><pubmed_authors>Valentine G</pubmed_authors><pubmed_authors>Kinney J</pubmed_authors><pubmed_authors>Fleming L</pubmed_authors><pubmed_authors>Toye AM</pubmed_authors><pubmed_authors>Ward L</pubmed_authors><pubmed_authors>Turner A</pubmed_authors><pubmed_authors>Danon L</pubmed_authors><pubmed_authors>Clout M</pubmed_authors><pubmed_authors>Helliker K</pubmed_authors><pubmed_authors>Maseko Z</pubmed_authors><pubmed_authors>Brzezinska J</pubmed_authors><pubmed_authors>Grimwood L</pubmed_authors><pubmed_authors>King J</pubmed_authors><pubmed_authors>Milutinovic K</pubmed_authors><pubmed_authors>Sequenza P</pubmed_authors><pubmed_authors>Hyams C</pubmed_authors><pubmed_authors>Mona T</pubmed_authors><pubmed_authors>Langdon A</pubmed_authors><pubmed_authors>Chang N</pubmed_authors><pubmed_authors>Qian G</pubmed_authors><pubmed_authors>Vasquez M</pubmed_authors><pubmed_authors>Friedrich Z</pubmed_authors><pubmed_authors>Riaz T</pubmed_authors><pubmed_authors>Bayley F</pubmed_authors><pubmed_authors>Minou K</pubmed_authors><pubmed_authors>Arachchge SN</pubmed_authors><pubmed_authors>Mackay V</pubmed_authors><pubmed_authors>Oliver J</pubmed_authors><pubmed_authors>Mitchell C</pubmed_authors><pubmed_authors>Szasz-Benczur Z</pubmed_authors><pubmed_authors>Hathaway A</pubmed_authors><pubmed_authors>Mattocks A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association of ABO and Rhesus blood groups with severe outcomes from non-SARS-CoV-2 respiratory infection: A prospective observational cohort study in Bristol, UK 2020-2022.</name><description>Despite significant global morbidity associated with respiratory infection, there is a paucity of data examining the association between severity of non-SARS-CoV-2 respiratory infection and blood group. We analysed a prospective cohort of adults hospitalised in Bristol, UK, from 1 August 2020 to 31 July 2022, including patients with acute respiratory infection (pneumonia [n = 1934] and non-pneumonic lower respiratory tract infection [NP-LRTI] [n = 1184]), a negative SARS-CoV-2 test and known blood group status. The likelihood of cardiovascular complication, survival and hospital admission length was assessed using regression models with group O and RhD-negative status as reference groups. Group A and RhD-positive were over-represented in both pneumonia and NP-LRTI compared to a first-time </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-06-14T05:28:34.247Z</modification><creation>2025-04-04T08:22:00.414Z</creation></dates><accession>S-EPMC7616671</accession><cross_references><pubmed>38009561</pubmed><doi>10.1111/bjh.19234</doi></cross_references></HashMap>